The mechanism of action and potential of EB2023, an OXPHOS inhibitor, in acute myeloid leukemia
Автор: VJHemOnc – Video Journal of Hematology & HemOnc
Загружено: 2025-12-17
Просмотров: 13
Matthew Villaume, MD, PhD, Vanderbilt University Medical Center, Nashville, TN, provides insight into EB2023, an inhibitor of oxidative phosphorylation (OXPHOS) that primes mitochondria for BCL2 dependence and induces pyroptotic cell death via AMPK signaling and the unfolded protein response. Dr Villaume highlights that EB2023 targets the last step of the OXPHOS pathway, ATP synthase, leading to energetic stress without causing oxidative stress, thereby potentially improving the agent's safety compared to other OXPHOS inhibitors. He also notes its potential synergy with venetoclax-based therapies in acute myeloid leukemia (AML), which he hopes will be investigated in future studies. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке:
